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Exact cause of rheumatoid arthritis, as well as other autoimmune diseases has not been 
identified yet. In last twenty years, epigenetics showed a new face of immune system. DNA 
methylation, modification of histones – proteins around which DNA is wrapped, 
or interference of small RNA sequences – microRNAs, these all are heritable changes outside 
the DNA sequence that provide another component involved in autoimmunity. Presented 
epigenetic mechanisms alter gene expression and thus facilitate production of pro-
inflammatory factors leading to autoimmune reactions. Moreover, genes regulating apoptosis 
are also frequently targeted by epigenetic modifications. Not only these mechanisms provide 
another level of immune defense, they also explain higher female susceptibility to 
autoimmune diseases and the influence of environment on pathogenesis of these diseases. 
Keywords: epigenetics, rheumatoid arthritis, systemic lupus erythematosus, autoimmune 
disease, DNA methylation, histone modification, microRNA
Abstrakt
Přesná příčina revmatoidní artritidy, jako i dalších autoimunitních onemocnění ještě
stále není identifikována. V posledních dvaceti letech epigenetika ukázala novou tvář 
immunitního systému. Dědičné změny mimo sekvence DNA poskytují další komponentu
hrající roli v autoimunitě. Metylace DNA, modifikace histonů – proteinů, kolem kterých je 
DNA obmotána, či interference malých sekvencí RNA – microRNA, všechny tyto 
mechanismy ovlivňují genovou expresi a tím umožňují zvýšenou produkci prozánětlivých 
faktorů vedoucích k autoimunitním reakcím. Kromě toho, geny regulující apoptózu jsou často 
cílem epigenetickách modifikací. Tyto mechanismy nejenže poskytují další úroveň imunitní 
obrany, ale poskytují také vysvětlení pro vyšší náchylnost žen k autoimunitním nemocím i 
vliv prostředí na patogenezi těchto nemocí. 
Klíčová slova: epigenetika, revmatoidní artritida, systémový lupus erythematodes, 
autoimunitní onemocnění, metylace DNA, modifikace histonů, microRNA
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1. Introduction
Since times of Waddington, the definition of epigenetics has changed to a great extent. 
Epigenetics was firstly considered only in terms of developmental biology, when it was 
perceived as sum of changes in gene expression, where epigenotype was defined as “set of 
organizers and organizing relations to which a certain piece of tissue will be subject during 
development make up” (Waddington 1939). The definition of epigenetics has varied since 
then, until 1996, when Russo et al. defined epigenetics as “the study of mitotically 
and/or meiotically heritable changes in gene function that cannot be explained by changes in 
DNA sequence” (Russo et al. 1996). Although the definition may still evolve nowadays, there 
is a general understanding of epigenetics as mechanism of regulation of gene expression by 
enabling access to transcription mechanism. 
Autoimmune disease (AD) is such condition, when body tissues are attacked by its 
own immune system. ADs are divided into two classes – systemic and organ-specific. The 
most abundant systemic ADs includes rheumatoid arthritis (RA), affecting mainly joints 
and surrounding tissues, systemic lupus erythematosus (SLE) affecting skin, joints, kidneys, 
heart, brain and many other important tissues. The class of organ-specific ADs includes 
multiple sclerosis (MS), affecting myelination of nerve cells in brain and spine, and type 1 
diabetes mellitus (T1DM) affecting pancreatic islets.
In last decades there have been a lot of attempts of finding out the mechanisms causing 
autoimmune diseases. Researchers carried out genome-wide studies discovering common 
genetic variants, mostly single-nucleotide polymorphisms (SNPs), predisposing humans to 
autoimmune diseases. Many of these studies identified human leukocyte antigens (HLA) gene 
regions playing key role in autoimmune diseases, but they have not yet provided tractable 
therapeutic targets (Danska and Poussier 2009). Anaya et al. tried to investigate whether 
common genetic basis of ADs exist (Anaya et al. 2006). However, as the mechanisms are still 
not understood precisely, such conclusion cannot be drawn, even when the co-occurrence of 
multiple ADs is not uncommon. Recently, there have also been mentions of epistasis, 
masking of disease-causing mutation by genetic interactions, playing role in autoimmune 
diseases. This matter has been reviewed with emphasizes on SLE and MS (Rose and Bell 
2012). 
There have been also some successful approaches to treating ADs, for example 
in cytokine-driven pathway – tumor necrosis factor (TNF) inhibitors in psoriasis (Cauza et al.
2002) or by knocking out the gene for Death Receptor 3 (DR3), the TNF receptor superfamily 
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member. Making the DR3 gene inoperative causes reduction in number of osteoclasts within 
areas susceptible to bone erosion (Bull et al. 2008).
Still, the exact cause of ADs remains unknown. Therefore, new approaches have been 
sought, epigenetics being one of them. In fact, epigenetic modifications bringing new insight 
in origin of ADs have triggered many studies in various research facilities. The aim of
the presented thesis is to explore the existent findings in the role of epigenetics in autoimmune 
diseases, with emphasis on rheumatoid arthritis. 
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2. Autoimmune Diseases
2.1 Systemic Autoimmune Diseases
Systemic AD is a condition, where multiple organs/tissues are attacked by body’s own 
immune system. This phenomenon is caused not only by disruption in mechanism protecting 
body from the autoimmune reactions, but also abnormalities in immune response to pathogens. 
The systemic ADs are characterized mainly by presence of autoantibodies involved in 
immunopathological activity in connective tissues. 
As mentioned above, RA and SLE belong to group of systemic diseases. 
However, the variety of systemic ADs is broad and it also includes conditions as scleroderma, 
polymyositis and mixed connective tissue disease. It appears that genes related to these 
diseases overlap, thus suggesting similar machinery in their pathogenesis. Researchers still 
find new overlaps of genes responsible for susceptibility to SLE and RA, e.g. in gene coding 
for B lymphoid tyrosine kinase (Orozco et al. 2011), enzyme playing role in B cell receptor 
signaling. However, the clinical manifestations and their severity differ in patients, indicating 
existence of multiple pathways in autoimmune pathogenesis. The clinical manifestations 
and severity may also change in one patient in time.
SLE is an autoimmune inflammatory disease affecting connective tissues all over 
the body. The cause of this condition is still unknown, however, some factors playing key role 
have been already discovered. Genetic background of SLE has been highly studied and the
research has already indicated that the within HLA genes class II, HLA-DRB1 allelic 
variations are increasing susceptibility to the disease (Fernando et al. 2007). HLA genes code 
for major histocompatibility complex (MHC) class II, typically expressed on antigen-
presenting cells. MHC molecules, binding peptides from outside of the cell, serve as ligands 
for receptors on T helper cells, which are then activated and able to assist in maturation of 
B cells and activation of cytotoxic T cells and macrophages.
However, genetic aspect of SLE is more complex. Genes like IRF5 (interferon 
regulatory factor 5) (Feng et al. 2010; Graham et al. 2006), STAT4 (signal transducer 
and activator of transcription 4) (Zheng et al. 2013), PTPN22 (protein tyrosine phosphatase 
non-receptor 22) (Shi et al. 2013) and CDKN1A (p21, cyclin-dependent kinase 
inhibitor 1) (Kim et al. 2009) are associated with increased risk of SLE. Furthermore, IRAK-1
(IL-1 receptor-associated kinase) gene encoded on X-chromosome has been identified as 
element in SLE pathogenesis (Jacob et al. 2009). The epistatic interaction between IRF5 SNP 
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rs77571059 and STAT4 SNP rs16833215 has been indicated (Kim et al. 2013). As if 
the genetics of SLE was not complicated enough, SNPs in PTPN22 gene region appear 
to differ across ethnicities in SLE patients (Namjou et al. 2013).
Scleroderma, or systemic sclerosis is another example of systemic autoimmune 
disease. It primarily affects skin, recruiting fibroblast and immune cells, resulting in 
thickening of skin by deposits of collagen, created by fibroblasts. Role of HLA genes is also 
significant in scleroderma. The HLA-DPB1 and DPB2 have been marked as main risk loci in 
Korean population, confirmed in US patients (Zhou et al. 2009). Th17 cells play interesting 
role in scleroderma. They produce pro-inflammatory cytokine IL-17A, which increases
production of matrix metalloproteinase 1 (MMP-1), pro-inflammatory cytokine IL-8 
and monocyte chemoattractant protein 1 but, on the other hand, Th17 cells also inhibit 
collagen type I production (Brembilla et al. 2013).
2.1.1 Rheumatoid Arthritis
Rheumatoid arthritis is a chronic inflammatory autoimmune disease resulting in 
irreversible joint destruction. In patients with RA, hyperplasia of the synovial lining occurs
(see Figure 1). The synovial tissue transforms due to activity of immune cells and synovial 
fibroblasts. Macrophages and synovial fibroblasts of synovial lining in junction of bone 
and cartilage proliferate from normal 1-3 cell layers up to 13 cell layers (Perlman and Pope 
2010). Current prevalence of RA is approximately 0.24 %, what corresponds to 4.8 million 
patients (Cross et al. 2014).
Figure 1: Hyperplasia of synovial lining and joint destruction in RA. Adopted from: 
(Schurigt 2013)
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There have been many histological studies carried out in order to find out the exact 
mechanism of cartilage destruction. Although a common or regular pattern for the cellular 
erosion of cartilage has not been found, it has been established that in the contact of 
the abnormal layer of synovial lining and intraarticular cartilage, there are also cell types other 
than macrophages and fibroblasts: mast cells, polymorphonuclear leukocytes and displaced 
chondrocytes. All of the mentioned cell types produce cartilage-degrading enzymes such as 
metalloproteinases and serine proteinases, regulated by various local mediators (Woolley 
and Tetlow 1997). In a recent study, two inflammatory axes (four synovial phenotypes) have 
been indicated: one dominated by B cells, second by macrophages and nuclear factor κB-
activating cytokines (e.g. TNF-α). Clinical responses to anti-TNF-α and anti-interleukin-6
(IL-6) receptor treatments differed within these two inflammatory axes (Dennis et al. 2014). 
These results suggest an explanation of drug response heterogeneity observed in RA patients, 
although further research is necessary.
Treatment using anti-TNF-α drugs has already reported some successful outcomes, 
though, without any long-term effect. The higher level of TNF-α in synovial tissues was 
detected already in 1991 (Chu et al. 1991). Besides other functions, the TNF-α-dependent 
pathways play role in inflammation and inhibition of apoptosis in synovial tissue. It has also 
been shown that pro-destructive function of TNF-α in synovial fibroblasts may be enhanced 
by other molecules, for example another pro-inflammatory cytokine, IL-33. (Kunisch et al.
2012). The serum concentrations of pro-inflammatory IL-6 family cytokines were also 
elevated in RA patients (Chung et al. 2011). However, recent study showed that IL-6 also 
induces production of anti-inflammatory IL-10 by type 1 regulatory T-cells, which are 
responsible for maintenance of tolerance (Krämer et al. 2013). Similarly to scleroderma, Th17 
cells appear to play significant role in RA pathogenesis, inducing activity of IL-6, IL-8, 
MMP-1 and MMP-3 (van Hamburg et al. 2011).
Next to the aforementioned, another aspect of RA pathogenesis has been proposed. 
The human endogenous retroviruses (HERVs), forming approximately 5-8 % of human 
genome, are elements and fragments inserted into our genome during evolution from 
exogenous viruses. Vast scale of processes has led to inactivation of almost every HERV 
element (Belshaw et al. 2004). Inactivation of these elements, however, is not irreversible. 
It was shown that infection by Epstein-Barr virus transcriptionally activated gene encoding 
envelope protein of an endogenous retrovirus (Sutkowski et al. 2001). The interference of 
some HERV elements within autoimmune diseases has been indicated in RA (Reynier et al.
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2009), SLE (Magistrelli et al. 1999; Pullmann et al. 2008), T1DM (Marguerat et al. 2004), 
MS (Brudek et al. 2009) and Sjogren’s syndrome (Moyes et al. 2005).
In clinical practice, there are several methods of diagnosis of RA in patients. One of 
the methods is use of autoantibodies, e.g. rheumatoid factor (Bruns et al. 2000) or anti-
citrullinated protein antibodies (ACPAs). Autoantibodies are antibodies, which identify 
body’s own tissues as foreign ones. These are tested with second generation anti-cyclic 
citrullinated peptide (anti-CCP-2) (Peoples et al. 2013). The antibody production in peripheral 
blood mononuclear cells (PBMCs) has been also connected with increase of TNF-like ligand 
1A levels in patients with RA. Yet, its function as disease activity marker has not been 
determined (Sun et al. 2013).
Genetic background of RA has been recently evaluated in a genome-wide association 
study (GWAS) with more than 100,000 subjects (Okada et al. 2014). Forty-two non-HLA
novel RA risk loci have been discovered. In total, 101 risk loci have been associated with RA 
susceptibility (Okada et al. 2014). These risk loci were cross-referenced with target drugs for 
RA. Twenty-seven of these drugs were associated with RA risk loci. Okada et al. also noted
that non-HLA RA risk loci explained 5-6% of heritability in RA (Okada et al. 2014). 
Conducting molecular pathway enrichment analysis, enrichment in T-cell related pathways, 
B-cell and cytokine signaling pathways have been observed (Okada et al. 2014).
Significant association of HLA class II genes with RA has been confirmed. Distinctive 
HLA class II types have been associated with susceptibility to variety of autoimmune diseases. 
Mainly increased expression of HLA-DRB1, the most prevalent beta component of MHC 
class II heterodimer, has appeared to have functional consequences on T cell immune 
response in RA patients (Kerlan-Candon et al. 2001). The HLA-DRB1 locus has many allelic 
variants. The hypothesis of “shared epitope” has been proposed in 1987, suggesting that 
allelic variants have similar amino acid sequence in third hypervariable region, critical for 
T cell recognition. This hypothesis indicated some allelic variants of HLA-DRB1 sharing 
similar epitope, which is responsible for RA susceptibility (Gregersen et al. 1987). The shared 
epitope hypothesis, however, has been questioned. Considering different allelic variants with 
shared epitope having distinct level of risk (Wordsworth et al. 1992), the question whether the 
shared epitope hypothesis is sufficient for explanation of RA susceptibility arose. In a recent 
study, it was discovered that five amino acid (AA) positions could explain RA susceptibility
in seropositive RA. These AAs are situated in HLA-DRB1 in positions 11, 71 and 74, in 
HLA-B in position 9 and in HLA-DPB1 also in position 9. All these AAs are situated in 
peptide-binding groove (Raychaudhuri et al. 2012).
11
Numerous studies concerning SNPs have been conducted. For example, it was 
demonstrated that SNP C1858T in PTPN22 gene is associated with RA (Song et al. 2013), 
SLE (Lea and Lee 2011), coeliac disease (Santin et al. 2008) and T1DM susceptibility (Qu 
et al. 2005). The PTPN22 gene codes for protein tyrosine phosphatase involved in signaling 
pathways within immune response. The protein tyrosine phosphatase suppresses signalization 
of Toll-like receptors in development of T cells in thymus and therefore the autoimmune 
T cells can survive. It was also indicated that combination of PTPN22, HLA-DRB1 and 
smoking increased risk of developing RA, however, no multiplication has been recognized 
(Morgan et al. 2009).
2.2 Organ-specific Autoimmune Diseases
Mechanisms of autoimmunity in systemic and organ-specific diseases appear not to 
differ much, however, the autoreactive immune cells, autoantibodies and pro-inflammatory 
cytokines are directed against single organ. Such diseases include T1DM, MS, coeliac disease, 
Crohn’s disease, Grave’s disease and myasthenia gravis.
Type 1 diabetes mellitus is an autoimmune type of diabetes, when autoimmune 
processes are aimed towards pancreatic β-cells producing insulin. The lack of insulin results 
in impairment of carbohydrate metabolism, which may end with several complications. 
Untreated T1DM may lead to ketoacidosis and organ damage. The tissue specific 
autoantibodies may be found in T1DM patients: islet cell antibodies (Castro et al. 2014) or 
glutamic acid decarboxylase autoantibodies (GADA). Genetic background of T1DM also 
includes HLA-related genes. The HLA-DQ8 alleles appear to be responsible for higher risk of 
T1DM (van Lummel et al. 2012), whereas HLA-DQ6 alleles may play role in protection from 
the disease (Pugliese et al. 1995). Other research indicated that combination of HLA-DRB1, 
HLA-DQA1 and HLA-DQB1 alleles may result in increased susceptibility as well as 
protection against T1DM (Erlich et al. 2008). The non-HLA genes also play significant role 
in T1DM. SNPs related to T1DM susceptibility were found for example in INS gene, coding 
insulin and IFIH1 (interferon induced with helicase C domain 1) gene, whose product serves 
for detecting viral mRNA and long dsRNA, activating type I interferon immune response. 
T1DM association with HLA-DRB1 gene, PTPN22 gene, INS gene and the variable numbers
of tandem repeats surrounding the INS gene was recently confirmed (Portuesi et al. 2013).
Genes responsible for cytokine signalization in immune system have also been identified as 
risk loci for T1DM (Barrett et al. 2009).
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Coeliac disease is another organ-specific AD. The organ affected by this disease is 
small intestine and patients with this disease cannot process gluten protein. Genetic 
predisposition to coeliac disease is represented by HLA-DQ2 (Karell et al. 2003) and DQ8
(Mazzarella et al. 2003) alleles and several non-HLA candidate gene risk loci are suspected.
Products of these HLA alleles present the gluten protein to T cells, activating them 
and causing autoimmune response. Increased expression of MMP-1 and 3 in coeliac disease 
patients may be responsible for villous atrophy (Daum et al. 1999), which is highly associated 
with this illness. Similar to other autoimmune diseases, the co-occurrence of multiple ADs is 
not uncommon. The co-occurrence with T1DM (Kota et al. 2012) and autoimmune thyroid 
disorders (Cuoco et al. 1999) has been noticed in coeliac disease. 
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3. DNA Methylation
DNA methylation is one of the most studied mechanisms of epigenetics. Researchers 
have already conducted wide variety of studies concerning DNA methylation in cancerous 
growth (Novak 2004), imprinting (Horsthemke 2014) and aging (Florath et al. 2014).
In eukaryotes, the DNA methylation occurs mainly on cytosine and guanine-rich 
regions of DNA. CpG islands are regions of very high CpG dinucleotide density, which mark 
mainly promoter regions and therefore their primary state is unmethylated, to allow 
transcription. CpG island hypomethylation is executed by DNA demethylation (Frank et al. 
1991). Methylation of regions with lower CpG density, which are within 2 kb distance from 
CpG islands, called CpG island shores appears to play a considerable role in gene expression 
(Irizarry et al. 2009). Methylation of CpG islands is responsible for long-term silencing, 
including X-chromosome inactivation. The highest occurrence of methylation is on 
heterochromatin regions of chromosomes, regions with silenced gene expression. The 
hypothesis that DNA methylation affects the active chromatin formation has already been 
examined (Keshet et al. 1986). In contrast to promoter regions of genes, the gene body has to 
be methylated for proper transcription. The reason for methylation is to avoid spontaneous 
initiation of transcription (Ball et al. 2009). DNA methylation pattern is not only specific to 
various regions of DNA, it is also tissue specific (Liang et al. 2011). This phenomenon is 
highly studied in embryogenesis and cellular differentiation.
The enzymes responsible for DNA methylation are called DNA methyltransferases 
(DNMTs), using S-adenosyl methionine (Magistrelli et al. 1999) as donor of methyl group, 
usually methylating fifth carbon atom of cytosine pyrimidine cycle. Several types of DNMTs 
have been identified in mammals. The DNMT3a and 3b are responsible for de novo
methylations of DNA (Xie et al. 1999) and DNMT1 is key enzyme responsible for 
maintenance pattern (Takeshita et al. 2011).
The overly enhanced methylation on certain loci – the hypermethylation is responsible 
for silencing of certain genes. The hypermethylation decreases the affinity for binding of 
transcription factors and increases recruiting of methyl-CpG binding proteins (MeCPs) to 
promoter regions, resulting in impaired transcription. Furthermore, the MeCPs show also 
a link between methylation and histone deacetylation, another epigenetic modification. It was 
shown that MeCP2 recognizing methylated DNA in nucleosome, recruits Sin3, 
a transcriptional regulatory protein, which associates with histone deacetylase, resulting in 
transcriptional silencing (Jones et al. 1998). MeCP2 has also been shown to be of importance 
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in maintaining DNA methylation pattern during cell division, forming complex with DNMT1 
and binding to hemimethylated DNA (Kimura and Shiota 2003).
Another important mechanism used in AD that is based on gene regulation, is increase 
of resistance to apoptosis. The promoter of gene for death receptor 3 (DR3), the member of 
apoptosis-inducing Fas gene family, has a specific methylation pattern, causing lower 
expression of DR3 protein in RA synovial cells (Takami et al. 2006). This pattern may 
attributed to apoptosis resistance in synovial cells. 
Hypermethylation pattern was discovered also in T1D, but the cause of increased level 
of methylation appears to be in homocystein metabolism. Homocystein is an intermediate 
in methionine catabolism and its lower serum levels were detected in T1D patients. The 
decrease of homocystein serum levels occurs due to increased activation of enzymes by trans-
sulfuration (Wijekoon et al. 2007).
On the other hand, not only increase in methylation can be found. The mechanism of
removing methylation from DNA appears to be a bit complicated than the reverse one. Some 
research indicates that activation-induced cytidine deaminase may play some role in 
demethylation and therefore induce gene expression. However, the actual role is not yet 
known (Isobe et al. 2013). Hypomethylation, especially low methylation of promoter causes 
higher expression of TNF-α. In study conducted by Nakano et al., methylomes, the patterns of 
DNA methylation, in fibroblast-like synoviocytes (FLS) differed in RA patients compared to 
control FLSs. Hypo- and hypermethylation was observed in 1859 loci in key genes relevant to 
RA, such as STAT3 (Signal transducer and activator of transcription 3), WISP3 (WNT1 
inducible signaling pathway protein), CHI3L1 (Chitinase 3-like protein 1), CASP1 (Caspase 
1), MAP3K5 (Mitogen-activated protein kinase 5) and MEFV (Mediterranean fever). 
Hypomethylation was associated with increased gene expression of factors contributing to RA 
pathogenesis. Increased hypomethylation occurred in several pathways related to cell 
migration and adhesion (Nakano et al. 2013). In RA patients, there has also been observed 
increased expression of DNMT1 and methyl-CpG-binding domain protein 2 mRNAs (Liu 
et al. 2011). This last finding indicates that regulation of methylation is not that simple 
and even when hypomethylation occurs in RA patients, the methylation enzyme and MeCPs 
levels are increased, what implies other level of regulation must be present in DNA 
methylation.
Though in RA the imbalance between hypo- and hypermethylation occurs, in SLE, 
hypomethylation appears to be the only abnormal methylation regulation mechanism.
For example, the hypomethylation of ITGAL gene was detected in T cells (Luo et al. 2008). 
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Product of this gene, integrin α L chain together with β chain, forms leukocyte function-
associated antigen (LFA-1). The LFA-1 functions as adhesion molecule in immune cells 
and plays role in transport to the infection site. In genome-wide SLE study, the 
hypomethylation was also marked in interferon type I genes (Absher et al. 2013). Interferons 
are glycoproteins produced by various cell types (lymphocytes, fibroblasts, macrophages, etc.) 
in response to variety of stimuli – e.g. viral infection. Using second messenger signal 
pathways, expression of anti-viral and immune modulatory genes occurs. 
Methylation patterns of genes coding cytokines, important molecules playing role in 
pathogenesis of inflammatory diseases, were also examined. Promoter region of IL6 gene, 
coding IL-6 involved in RA pathogenesis as pro-inflammatory cytokine, displayed 
hypomethylation of single region, leading to increased serum IL-6 levels (Ishida et al. 2012). 
Furthermore, there has been shown that hypomethylation of proximal CpG motif of promoter 
of gene encoding IL-10, anti-inflammatory cytokine, may also have a regulatory function in 
RA (Fu et al. 2011). This finding was further examined in study of SLE, where 
hypomethylation of IL10 gene together with IL-1 receptor type 2 (IL1R2) gene accompanied 
greater disease activity. Moreover, the detected hypomethylation of IL1R2 gene was more 
significant in RA patients than in SLE patients and healthy controls (Lin et al. 2012). Further 
research indicated increased hypomethylation in yet another cytokine pathway, interferon 
signaling type I in SLE patients (Absher et al. 2013). 
Not only cytokine activity, but also chemokine activity is increased in RA synovial 
cells. For example cytokine CXCL12, also known as stromal-derived factor 1, occurs in 
higher level in patients with RA (Lisignoli et al. 2004). This chemokine appears to have 
multiple functions: attraction and activation of leukocytes, recruiting of macrophages
and increase of metalloproteinase expression. Similarly to cytokine genes, the promoter 
of CXCL12 gene is regulated by methylation, when the expression of CXCL12 can be 
increased by demethylation (Karouzakis et al. 2011).
Another aspect has been shown to contribute to lowered methylation of DNA in RA 
patients. The metabolism of polyamines, enhanced in RA synovial fibroblasts, in which SAM 
molecules are consumed, offers an explanation of hypomethylation (Karouzakis et al. 2012). 
By consumption of SAM molecules, the access to methyl group donor for DNMTs is reduced, 
therefore hypomethylation occurs.
Most of the research is conducted in patients with already diagnosed autoimmune 
disease. Therefore, the primary impulse leading to autoimmunity remains unclear. In T1DM, 
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it was detected that variable positions of DNA methylation are enriched even before disease 
diagnosis (Rakyan et al. 2011). 
The effect of methylation has also been demonstrated in promoters of CD40L gene, 
located on X chromosome. The gene product, ligand of CD40 receptor (CD40L), causes 
multiple immune cell activation. The hypomethylation in CD40L promoter has been shown in 
female scleroderma patients (Lian et al. 2012) , as well as in RA female patients. 
The hypomethylation led to increased expression of CD40L in CD4(+) T cells of female RA 
patients (Liao et al. 2012). In SLE, hypomethylation in CD40L gene doubled the CD40L 
expression in women (Lu et al. 2007). Authors of this study explained that main reason for 
such findings is that female genome includes two X chromosomes and therefore 
hypomethylation of this gene activates gene expression on both of these chromosomes. 
The effect of increased CD40L expression is therefore responsible for increased immune cell 
activation, which may lead to autoimmunity. Findings in these studies indicate that CD40L 
may give a possible explanation for higher level of female susceptibility in some autoimmune 
diseases. The overexpression of CD40L in women, compared to men was recently confirmed 
in lupus patients (Hewagama et al. 2013).
There is still no exact explanation of gender-specific susceptibility. ADs appear to 
have multiple levels of regulation; thus, existence of a single explanation is improbable. Still, 
X-chromosome inactivation is perceived as the main reason for this phenomenon. 
The example of CD40 ligand indicates that this viewpoint could be worth further research. 
The inactivation of most genes on one chromosome in females is believed to occur due to 
dosage compensation of products of X-linked genes. The dosage compensation theory 
proposes that the X-chromosome inactivation occurs due to need of equal gene expression in 
both sexes, as the X-chromosome has approximately 2.6 times more base pairs. Thus, X-
chromosome inactivation equals the expression between sexes. The increased methylation, 
causing inactivation of chromatin, was observed in genome study of DNA methylation 
profiles on X-chromosomes (Sharp et al. 2011).
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4. Histone Modifications
Histones, package proteins around which DNA is wound, were discovered in 1884 by 
Albrecht Kossel. There are several types of histones forming chromatin structural units –
nucleosomes. The basic classification of histone proteins separates them into two groups: core 
proteins, forming octameric nucleosome core, around which DNA is wound, and linker 
histones sustaining the structure of nucleosomes. Among the former, there are four families 
of proteins: H2A, H2B, H3 and H4. The latter group of histones is formed only by H1 family 
of histone proteins. There are many types of modifications, which can occur at histones.
Several modifications can occur at one promoter or enhancer region at the same time (Wang 
et al. 2008). These modifications thus create some kind of ‘code’ read by binding proteins, 
which include transcription machinery. Because of various combinations of modification, 
there are plenty possible variations in transcription.
4.1 Acetylation
Histone acetyltransferases (HATs), enzymes responsible for histone acetylation,
neutralize the positive charge on amino acid lysine in sequence of histone protein, by 
transferring acetyl group from acetyl coenzyme A. This causes loosening of DNA-histone 
interaction, allowing access to transcription machinery. Besides RNA polymerase,
the transcription machinery includes various transcription factors, what results in 
enhancement of transcription. The histone acetylation mechanism, however, appears to be 
connected with methylation status of DNA. Heterochromatin regions of DNA are not only 
methylated, but histone deacetylation occurs. The euchromatin regions are demethylated and
histone tails are acetylated (see Figure 2).
Figure 2: Epigenetic modifications in euchromatin and heterochromatin. Adopted from: 
(Schroeder et al. 2012)
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The acetylation of histones appears to regulate activity of transcription factor FOXP3 
(scurfin), which plays key role in regulation of development and function of regulatory T cells
(van Loosdregt et al. 2010). The regulatory T cells expressing FOXP3 are involved 
in immune self-tolerance mechanisms, thus abnormal function of FOXP3 may lead to 
autoimmune reactions. Hyperacetylation of histones in FOXP3 locus turned out to prevent 
polyubiquitination, therefore inhibiting protein degradation and disrupting stability in FOXP3 
level (van Loosdregt et al. 2010). 
Abnormal cytokine regulation is also examined in histone modifications. The higher 
level of H3 histone acetylation in promoter region of IL6 gene has been detected in RA
synovial fibroblasts compared to non-autoimmune osteoarthritis. This hyperacetylation 
indicates loosened state of promoter, accessible for transcription (Wada et al. 2014). 
Expression of this pro-inflammatory cytokine is increased by combination of epigenetic 
mechanisms and therefore IL-6 is a possible target in developing new treatment of 
autoimmune inflammatory diseases.
Hyperacetylation of histones also occurs in INFG gene, coding for interferon γ (Zhou 
et al. 2004). Interferon γ (type II interferon) plays substantial role in immunoregulation and is 
secreted by variety of immune cells – macrophages, type 1 helper T cells, cytotoxic T cells, 
natural killer cells and others.
Acetylation of histones may not only serve as regulator of access for transcription 
machinery. In SLE, nucleosomes have been identified as autoantigens (Bruns et al. 2000). 
Using monoclonal antibodies, apoptosis-induced acetylation of H2BK12 (van Bavel et al.
2009) and acetylation of three lysine residues (from 1st  to 22nd residue position) on H4
(Dieker et al. 2007) was presented as target epitope for autoantibodies in SLE patients.
Histone acetylation seems to be a component in autoimmune processes involved in
multiple sclerosis. It is a condition, where myelin sheath of nerve cells is damaged by 
autoimmunization. The acetylation of promoter region of H3 has been detected in NogoA(+) 
oligodendrocyte in white matter. This acetylation was associated with increased level of 
oligodendrocyte differentiation transcriptional inhibitors and high expression of HAT mRNAs. 
However, the acetylation decreased in cells with active demyelination and remyelination 
(Pedre et al. 2011). Acetylation of H3 histone may provide an epitope responsible
immunoreactivity in MS. Interestingly, hypoacetylation pattern of H3 and H4 was found in 
SLE patients (Hu et al. 2008).
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Much more studied mechanism in histone acetylation is inhibition of enzyme with 
antagonistic function compared to the HATs - histone deacetylases (HDACs). Mechanism of 
their functioning is removing acetyl group from acetyl-lysine, leading to stabilization of 
chromatin and silencing respective genes.
As the mechanism of HDACs is inhibition of transcription, according to previous 
findings, low expression is expected in autoimmune patients. In RA patients, reduction in the 
HDAC activity compared to non-autoimmune osteoarthritis patients and healthy controls 
occurred in synovial tissue specimen (Huber et al. 2007a). However, higher expression 
of HDAC1 and the induction of HDAC1 activity by TNF-α stimulation in synovial fibroblasts 
have been detected in RA patients (Kawabata et al. 2010). Cell proliferation and survival of 
activated synovial fibroblasts in RA was impaired by HDAC1 knockout and suppression of 
MMP production was also detected (Horiuchi et al. 2009). Decreased recruitment of HDAC1, 
probably causing H3K18 hyperacetylation together with low recruitment of DNMT3a, 
possibly resulting in H3K27 hypomethylation, was observed in IL17A gene promoter. These
modifications allow binding of (CREM)α transcription factor, which induces pro-
inflammatory IL-17A expression (Rauen et al. 2011). All these findings indicate that HDAC1 
activity may play role in far more complicated pathway than understood nowadays. 
The main support for acetylation of histones playing role in autoimmune diseases has 
been shown in treatment using inhibitors of HDACs. This matter will be discussed in chapter 
on current and potential treatment.
4.2 Methylation
Unlike acetylation and deacetylation, histone methylation does not change the charge 
of any amino acid. It occurs usually at lysine, arginine on H3 and H4 types of histones. The 
knowledge of histone methylation effects in autoimmune diseases is very limited. Most of the 
research on topic of histone methylation occurs in cancer studies. The enzymes responsible 
for histone methylation are divided into two groups. First group unites histone lysine 
methyltransferases, the second group contains histone arginine methyltransferases. As well as 
DNA methyltransferases, they use SAM as methyl group donor. Antagonist function is 
provided by histone demethylase.
Genome-wide study of SLE H3K4 trimethylation in PBMCs indicates that there were
significant alterations in H3K4me3 in SLE-related genes PTPN22 and LRP1B (LDL receptor-
related protein B1), compared to healthy controls and RA patients (Dai et al. 2010). Increase 
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in recruitment of the H3K4 methyltransferase SET7/9 was observed in murine diabetes model 
(Li et al. 2008). Another research indicated that SET7/9 may prevent histone deacetylation by 
sirtuin 1 and therefore lead to type II collagen α1 expression (Oppenheimer et al. 2014).
Not only histone methylation alone, bud combination of histone methylation and acetylation 
in gene for CD70 appears to contribute to development of SLE (Zhou et al. 2011). CD70 is 
protein from TNF superfamily and serves as ligand for receptor CD27. The ligation of this 
receptor induces NK cell proliferation and production of interferones, serves as co-stimulus 
for effector T cell production and also contributes to B cell maturation. Besides histone 
modifications, hypomethylation of CD70 promoter appears to contribute to autoimmune 
response. Promoter hypomethylation leading to CD70 overexpression was detected 
in scleroderma (Jiang et al. 2012). In RA patients, H3K27 histone trimethylation repressed
expression of pro-fibrotic factor fra-2. Therefore, inhibition of histone trimethylation on 27th
lysine residue in H3 histone contributes to inhibition of fibroblast activation (Krämer et al.
2013). The methylation of 4th lysine of H3 by Ash1l methyltransferase indicated the 
suppression of IL-6 production, therefore having anti-inflammatory effect (Xia et al. 2013).
4.3 Deimination
Human peptidylarginine deiminases, especially PAD2 and PAD4 have been shown to 
be expressed in synovial tissue of RA patients. PADs catalyze posttranslational modification 
of peptidylarginine into peptidylcitrulline. PAD4 citrullinates proteins, contributing to 
creating of autoantibody specific epitopes (Schellekens et al. 1998). The hypercitrullination of 
histones by PAD4 was detected in neutrophils. This increase in citrullination was linked to 
decondensation of chromatin, used in creation of neutrophil extracellular traps, which play 
role in immune response to bacterial infection (Leshner et al. 2012; Wang et al. 2009).
4.4 Oxidative Modification
Besides rather ‘classical’ histone modifications, there are plenty substances capable of
modifying protein structure. One of these compounds is peroxynitrite with powerful nitrating 
and oxidizing effect. It has been shown that autoantibodies in SLE bind preferably to histone 
H1 modified by peroxynitrite (Khan et al. 2014). This preference of autoantibodies towards 
oxidatively modified histone proteins was also demonstrated in RA when H2A histone protein 
was modified with peroxynitrite (Khan et al. 2012).
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5. MicroRNAs
MicroRNAs or micro ribonucleic acids are small, 18 to 23 base-pair long non-coding 
molecules that serve as post-transcriptional regulators of gene expression. Their first link to 
autoimmune diseases occurred in 2006, when connection between autoantibodies and RNA 
interference was observed (Jakymiw et al. 2006). The usual mechanism of microRNA 
interference is its binding to 3’ untranslated region (UTR) of target mRNA with assistance of 
RNA-induced silencing complex (RISC) (Gregory et al. 2005). This process results in mRNA 
destabilization and/or inhibition of translation. 
The upregulation of some microRNAs has been discovered in patients with RA. 
Elevated miR-146a, miR-155, miR-132 and miR-16 expression in PBMCs was detected. 
Despite increased expression of miR-146a, levels of its two targets – TNF receptor-associated 
factor 6 (TRAF6) and IRAK-1 did not differ in RA patients and healthy individuals. However, 
the repression of TRAF6 and IRAK-1 genes in THP-1 cells (derived from acute monocytic 
leukemia and used in immunohistochemistry to mimic native monocyte-derived macrophages) 
reduced TNF-α production (Pauley et al. 2008). In vitro studies also showed that TNF-α
upregulated miR-146a expression (Li et al. 2010), therefore TNF-α appears to regulate its 
own level with help of miR-146a. Furthermore, the overexpression of miR-146a was 
associated with suppression of T cell apoptosis (Li et al. 2010). Another target of miR-146a 
activation, signal transducer and activation transcription 1 (STAT1), was suggested to 
facilitate a pro-inflammatory regulatory T cell phenotype. This study was conducted in 
patients with active RA, where decreased expression of miR-146a was detected (Zhou et al.
2014).
Level of miR-124a was found to be lower in RA patients. There are indications of this 
microRNA functioning as suppressor of cyclin-dependent kinase 2 and monocyte 
chemoattractant protein 1 production, having binding site in 3’ UTR of their 
mRNA (Nakamachi et al. 2009).
Higher expression of miR-155 in RA patients was associated with repression of MMP-
3 synthesis, thus suggesting involvement in destruction of extracellular matrix, mainly 
collagen in joints (Stanczyk et al. 2008). The upregulation of miR-155 appeared also in MS, 
where it targeted two sites in 3’ UTR in CD47 mRNA. The CD47 serves as “don’t eat me” 
signal for macrophages. Deregulation of this inhibitory signal thus allows destruction of 
myelin, carried out by macrophages (Junker et al. 2009). In model of autoimmune 
encephalomyelitis, knockdown of miR-155 expression resulted in decrease in number of Th1 
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and Th17 cells (Zhang et al. 2014). Suggesting similar function in MS, the miR-155 
regulation has potential in MS therapy. Matrix remodeling in coeliac disease, another 
autoimmune disease, which affects small intestine, appears to be connected with regulation of 
cluster of microRNAs – miR-192/194 (Vaira et al. 2014). 
Regulation function of microRNA in other epigenetic modifications is emerging in 
recent research. To achieve hypomethylation effect, several microRNAs are involved. The 
downregulation of DNMT1 level has been detected in correlation to increased levels of miR-
21, miR-148a (Pan et al. 2010) and miR-126 (Zhao et al. 2011). However, these three 
microRNAs decrease DNMT1 level in their own way. Indirect increase in DNMT1 level is 
performed by miR-21, targeting autoimmune gene RASGRP1, whereas miR-148a and miR-
126 target directly DNMT1 mRNA (see Figure 3).
Figure 3: Regulation of DNMT function by microRNAs. Adopted from: (Shen et al. 2012)
In last few years, research of microRNA function in autoimmune diseases brought 
variety of deregulations in wide range of microRNA molecules; however, the targets of their 
regulation in autoimmune diseases are still unknown. Such examples may be seen in
downregulation of miR-363 and miR-498 in CD4(+) T cells of RA patients (Li et al. 2010).
Not that all the epigenetic machinery was complicated enough, the different 
expression of microRNAs was shown in SLE patients with distinct types of autoantibodies. 
The patients with autoantibodies against dsDNA expressed higher levels of miR-155 
and miR-146a, whereas patients with autoantibodies against RNA-associated antigens 
expressed miR-493 and miR-939 in higher levels (Chauhan et al. 2014).
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6. DNA vs. Environment
The question of nature vs. nurture – their influence on human phenotype has been 
a dispute in scientific circles for a long time. The pattern of heredity discovered by Gregor 
Mendel, although brought to light 16 years after his death, inclined the general scientific 
opinion towards the “nature”. Nevertheless, the concept of “nurture” influencing human 
development did not diminish. Numerous twin, starvation, viral and smoking studies have 
been carried out, indicating the environment playing an important role in human phenotype 
and diseases.
Although there has been evidence of correlation between the environmental factors 
and phenotype, an exact mechanism how external factors execute the modifications was 
missing until the discovery of epigenetics, which provides a new approach.
The concept of healthy diet has been part of general knowledge for a long time. 
Nowadays, besides effects of vitamins and various inorganic compounds in diet, epigenetics
reveals new mechanisms of food affecting disease susceptibility. When administrating methyl 
donor-rich food to pregnant Agouti mice, increase of DNA methylation on long terminal 
repeat in viable yellow allele of Agouti gene occurs. This results in increase of darker brown 
coat phenotypes in offspring. The higher the methylation supplement, the higher number of 
dark brown coat phenotypes (Cooney et al. 2002). Methyl-deficient diet also appears to 
influence genes with oncogenic functions. The higher expression of genes encoding IGF2 
(insulin-like growth factor 2) and H19 (small non-coding RNA) was associated with 
significant decrease in histone methylation of promoters of given genes (Dobosy et al. 2008).
Cruciferous vegetables contain sulforaphane, HDAC inhibitor, whose activity leads to 
cancer prevention (Horiuchi et al. 2009). Sulforaphane also appears to inhibit hyperplasia in 
synovial cells, T cell activation and TNF and IL-17 production in CD4(+) T cells in RA 
patients (Kong et al. 2010). Another HDAC inhibitor, butyrate, led to inhibition of cell 
proliferation in breast cancer. Vitamin A enhanced this effect significantly (Andrade et al.
2012). Curcumin, a substance found in plant Curcuma longa is often used in spice in Indian 
cuisine. Curcumin modulates transcription factor T-bet that plays role in differentiation of 
pro-inflammatory Th1 cells. Therapeutic effect of curcumin in T1DM was detected in murine 
model (Castro et al. 2014). Curcumin functions as HAT inhibitor and recently, its reducing 
effect on acetylation of H3 in IL6 promoter was detected (Wada et al. 2014).
Not only diet, but also other environmental influences affect our susceptibility to 
diseases. Tobacco smoking, for example, lowers methylation in single locus of F2RL3 gene 
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(Breitling et al. 2011). This gene encodes protease activated receptor 4 (PAR-4). Signaling 
through this receptor was detected in several clotting mechanisms, therefore its increased 
expression may lead to increase of cardiovascular disease. 
As we can see, environment plays role in epigenetic changes in our body. While our 
bodies are subjected to outside world, our cells also undergo aging. The 52 % increase in 
methylation was detected in age-associated CpGs (Florath et al. 2014).
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7. Current and Potential Treatment
Since the classification of the ADs, there have been numerous efforts to create 
an ultimate treatment to cause long-term remission in ADs. Such treatment is still unavailable, 
but new approaches as epigenetic treatment may lead towards the success in this goal.
The most frequent treatments used currently in RA patients include disease-modifying 
anti-rheumatic drugs (DMARDs), which function rather on cellular and cytokine level, 
reducing synovitis and systemic inflammation and appear not to have effect on epigenetic 
modifications. The most aggressive DMARD is methotrexate, which can be combined with 
other drugs to improve function. Methotrexate inhibits dihydrofolate reductase that is 
important component in de novo purine synthesis. Recently, a clinical trial showed that use of 
tofacitinib, a Janus kinase inhibitor, together with methotrexate, improved signs 
and symptoms of RA in 6 months with relatively manageable safety (Burmester et al. 2013).
As the mechanism of methotrexate function includes inhibition of DNA and RNA synthesis, 
severe side-effects are part of therapy. It was originally developed as chemotherapeutic agent, 
so suppression of immunity is part of the treatment (Herman et al. 2004).
First approved anti-TNF drug is adalimumab. It is a monoclonal antibody, which binds 
to TNF-α, thus inhibiting pro-inflammatory reactions. There are now two other antibody-
based anti-TNF drugs used in clinical practice - golimumab and infliximab. Adalimumab 
and golimumab are human immunoglobulins, whereas infliximab is a chimeric antibody from 
mice and human. Another chimeric monoclonal antibody rituximab, drug primary developed 
for cancer treatment, was repurposed for RA (Okada et al. 2014). Rituximab is an antibody 
recognizing B-lymphocyte antigen CD20, and the treatment ends up with elimination of B 
cells, highly activated in autoimmune response.
In addition to methotrexate and antibodies, non-epigenetic treatment includes several 
other approaches. One of them is based on inhibition of cyclin-dependent kinases (CDKs), 
which play role in cell cycle, division and differentiation of blood cells, including 
lymphocytes. Flavopiridol, a CDK6/4 inhibitor suppresses synovial hyperplasia and joint 
destruction in mouse models (Sekine et al. 2008). Besides the aforementioned, symptomatic 
treatment by steroidal and non-steroidal anti-inflammatory drugs is used in clinical practice. 
Epigenetic treatment is yet in its beginnings and development of these drugs is still in 
trial phase. Inhibition of HDACs was mentioned above as mechanism of hyperacetylation 
in cells. Vorinostat (suberanilohydroxamic acid – SAHA) is HDAC inhibitor associated with 
NF-kappa B subunit p65 hyperacetylation. Its administration in non-obese diabetic mouse 
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(murine model of T1DM) reduced diabetes incidence by 38 % and increased pancreatic 
insulin content by 200 %. The study indicated immune response involving increase of 
transcription factors Gata3 and FOXP3, and decrease of pro-inflammatory cytokines IL-6, IL-
12 and TNF-α (Christensen et al. 2014). Another HDAC inhibitor, entinostat (MS-275) has 
been shown to reduce inflammation reaction in rats with experimental autoimmune neuritis 
(Dai et al. 2010). These two HDAC inhibitors appeared to be related to suppression of p38 
mitogen-activated protein kinase (MAPK) signaling pathway and chemotaxis (Choo et al.
2013). Selective HDAC6 inhibitor, tubastatin, also showed anti-inflammatory and anti-
rheumatic effects in mice models, including inhibition of IL-6 production (Vishwakarma et al.
2013). Givinostat is another member of HDAC inhibitor family. Its activity was examined in 
experiments, trying to explore the mechanism of induction of T1DM by viral infection. 
The combined administration of givinostat and Killham rat virus in rat models resulted in 
protection from T1DM by preventing viral infection of pancreatic islets (Hara et al. 2014).
The production of extracellular matrix, mainly collagen, was reduced by another HDAC 
inhibitor, trichostatin A in mouse model (Huber et al. 2007b). Trichostatin A also reduced 
hypoacetylation on H3 and H4, improving disease phenotype in murine lupus model (Garcia 
et al. 2005). Another effect of trichostatin A was detected in FLS and macrophages, where it 
significantly weakened IL-6 transcript stability (Grabiec et al. 2012).
Recently, hypomethylation agent 5-aza-2’-deoxycytidine exhibited therapeutic effects 
in murine models of multiple sclerosis. Treatment with this agent also caused 
hypomethylation in CpG island of FOXP3 gene (Mangano et al. 2014).
The development of microRNA targeting drugs is highly in demand. The first drug of 
this kind, miravirsen was discovered targeting miR-122 expressed in liver. Use of miravirsen 
is currently in stage of clinical trials for treatment of infection by hepatitis C virus (Lindow 
and Kauppinen 2012). Therefore, drugs targeting microRNAs provide highly potential 
treatment opportunities in autoimmune diseases. 
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8. Conclusion
Understanding of autoimmune diseases is currently perceived in multiple levels. 
Epigenetic modifications appear to play significant role in pathogenesis of autoimmune 
disease. Impaired function of methylation enzymes provides accessibility for transcription 
machinery, what allows higher expression of cytokines, microRNAs and multiple 
transcription factors playing role in pathogenesis of autoimmune diseases. Not only 
demethylation is responsible for increased expression. Histone acetylation is another 
epigenetic mechanism contributing to pathogenesis. Higher susceptibility to autoimmune 
diseases in women appears to be caused by pathogenous factors encoded on X chromosome. 
Its double count in women presents double opportunity for epigenetic modifications activating 
their transcription. Furthermore, acetylation together with other histone modifications 
provides epitopes for autoantibody recognition. Variety of microRNAs has been discovered to 
be deregulated in autoimmune diseases. Although their function is still unclear, microRNAs 
appear to affect all levels of regulation. This relationship is, however, mutual. All epigenetic 
mechanisms seem to co-operate, creating a destructive autoimmune machinery complicating 
lives of millions of people. Although the level of regulation in autoimmune diseases 
is complex, epigenetics appears to explain relation of diet, smoking and other environmental 
factors to these diseases.
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9. List of Used Abbreviations
ACPA anti-citrullinated protein antibody
CD (e.g. CD40) cluster of differentiation (e.g. cluster of differentiation 40)
CD40L ligand to CD 40 receptor
CDK cyclin dependent kinase
CXCL12 CXC-motif chemokine 12, stromal cell-derived factor 1
DMARD disease modifying antirheumatic drug
DNMT DNA methyltransferase
DR3 death receptor 3
FLS fibroblast-like synoviocytes
FOXP3 forkhead box P3 - transcription factor scurfin
H2A/2B/3/4 histone type 2A/2B/3/4
H2BK12 lysine residue on position 12 on H2B type histone
H3K4me3 trimethylation on lysine residue on position 4 on H3 histone
HAT histone acetyltransferase
HDAC histone deacetylase
HERV human endogenous retrovirus
HLA-DRB1/DPB1 human leukocyte antigen type DRB1/DPB1
IL (e.g. IL-6) interleukin (e.g. interleukin-6)
IRAK-1 IL-1 receptor-associated kinase 1
IRF interferon regulatory factor
MAPK mitogen-activated protein kinase
MeCP methyl-CpG binding protein
MHC major histocompatibility complex
MMP matrix metalloproteinase
PAD peptidylarginine deiminase
PBMC peripheral blood mononuclear cell
PTPN22 protein tyrosine phosphatase non-receptor 22
SAM S-adenosyl methionine
STAT signal transducer and activator of transcription
Th1 T helper cell 1
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